Weber, Fabio J; Latshang, Tsogyal D; Blum, Manuel; Kohler, Malcolm; Wertli, Maria M (2022). Prognostic factors, disease course and treatment efficacy in Duchenne muscular dystrophy: A systematic review and meta-analysis. Muscle & nerve, 66(4), pp. 462-470. John Wiley & Sons 10.1002/mus.27682
|
Text
Weber_MuscleNerve_2022.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview |
|
|
Text
Muscle_and_Nerve_-_2022_-_Weber_-_Prognostic_factors_disease_course_and_treatment_efficacy_in_Duchenne_muscular_dystrophy_.pdf - Accepted Version Available under License Publisher holds Copyright. Download (1MB) | Preview |
INTRODUCTION/AIMS
Prognostic factors in Duchenne muscular dystrophy (DMD) predict the disease course and may help individualize patient care. The aim was to summarize the evidence on prognostic factors that may support treatment decisions.
METHODS
We searched six databases for prospective studies that each included ≥50 DMD patients with a minimum follow-up of one year. Primary outcomes were age at loss of ambulation (LoA), pulmonary function (forced vital capacity percent of predicted, FVC%p), and heart failure.
RESULTS
Out of 5074 references, 59 studies were analyzed. Corticosteroid use was associated with a delayed LoA (pooled effect HR 0.42, 95% CI 0.23 to 0.75, I2 94%), better pulmonary function tests (higher peak FVC%, prolonged time with FVC%p >50%, and reduced need for assisted ventilation) and delayed cardiomyopathy. Longer corticosteroid treatment was associated with later LoA (>1 year compared to <1 year; pooled HR: 0.50, 95% CI 0.27 to 0.90) and early treatment start (aged <5 years) may be associated with early cardiomyopathy and higher fracture risk. Genotype appeared to be an independent driver of LoA in some studies. Higher baseline physical function tests (e.g., 6-minute walk test) were associated with delayed LoA. Left ventricular dysfunction and FVC <1 liter increased and the use of angiotensin-converting enzyme (ACE) inhibitors reduced the risk of heart failure and death. Fusion surgery in scoliosis may potentially preserve pulmonary function.
DISCUSSION
Prognostic factors that may inform clinical decisions include age at corticosteroid treatment initiation and treatment duration, ACE-inhibitor use, baseline physical function tests, pulmonary function, and cardiac dysfunction. This article is protected by copyright. All rights reserved.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine 04 Faculty of Medicine > Medical Education > Institute of General Practice and Primary Care (BIHAM) |
UniBE Contributor: |
Blum, Manuel, Wertli, Maria Monika |
Subjects: |
600 Technology > 610 Medicine & health 300 Social sciences, sociology & anthropology > 360 Social problems & social services |
ISSN: |
0148-639X |
Publisher: |
John Wiley & Sons |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
25 Jul 2022 12:25 |
Last Modified: |
22 Jul 2023 00:25 |
Publisher DOI: |
10.1002/mus.27682 |
PubMed ID: |
35860996 |
Uncontrolled Keywords: |
Duchenne muscular dystrophy Morbus Duchenne mortality outcome prognostic factor |
BORIS DOI: |
10.48350/171469 |
URI: |
https://boris.unibe.ch/id/eprint/171469 |